Table:
|  | March 31, |  |
| --- | --- | --- |
|  | 2019 | 2018 |
| Nippon Yttrium Co., Ltd ("NYC") | $8,215 | $8,148 |
| NT Sales Co., Ltd ("NTS") | 1,218 | 998 |
| Novasentis | 977 | 2,870 |
| KEMET Jianghai Electronics Components Co., Ltd (“KEMET Jianghai”) | 2,515 | — |
|  | $12,925 | $12,016 |
Paragraphs:
Note 6: Equity Method Investments
The following table provides a reconciliation of equity method investments to the Company's Consolidated Balance Sheets (amounts in thousands):
TOKIN's Joint Ventures - NYC and NTS
As noted in Note 2, “Acquisitions,” on April 19, 2017, the Company completed its acquisition of the remaining 66% economic interest in TOKIN and TOKIN became a 100% owned subsidiary of KEMET. TOKIN had two investments at the time of acquisition: NYC and NTS. The Company accounts for both investments using the equity method due to the related nature of operations and the Company's ability to influence management decisions.
NYC was established in 1966 by TOKIN and Mitsui Mining and Smelting Co., Ltd (“Mitsui”). NYC was established to commercialize yttrium oxides and the Company owns 30% of NYC's stock. The carrying amount of the Company's equity investment in NYC was $8.2 million and $8.1 million as of March 31, 2019 and 2018, respectively.
NTS was established in 2004 by TOKIN, however subsequent to its formation, TOKIN sold 67% of its stock. NTS provides world-class electronic devices by utilizing global procurement networks and the Company owns 33% of NTS' stock. During the year ended March 31, 2019, a significant portion of NTS' sales were TOKIN’s products. The carrying amount of the Company's equity investment in NTS was $1.2 million and $1.0 million as of March 31, 2019 and 2018, respectively.
Question:
What was the change in the investments into Novasentis between 2018 and 2019?
Answer: 977-2870 = -1893